Pluri Secures Israel Funding for MAIT Cell Cancer Therapy, Teams Up with Bar-Ilan University to Target Solid Tumors
Portfolio Pulse from Benzinga Newsdesk
Pluri Inc. has secured funding from the Israel Innovation Authority for its collaboration with Bar-Ilan University to develop MAIT cell therapies targeting solid tumors. This partnership aims to enhance the efficacy of CAR-MAIT cell therapy using novel technologies.
October 28, 2024 | 11:03 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Pluri Inc. has received funding from the Israel Innovation Authority to collaborate with Bar-Ilan University on developing MAIT cell therapies for solid tumors. This partnership could enhance Pluri's CAR-MAIT cell therapy platform, potentially increasing its efficacy and tumor specificity.
The funding and collaboration with Bar-Ilan University are significant for Pluri as they enhance the development of their MAIT cell therapy platform. This could lead to advancements in treating solid tumors, a major unmet medical need, potentially boosting investor confidence and stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100